86223-05-4

Usage

Uses

Used in Pharmaceutical Industry:
P-HYDOROXYPHENYL-4-BUTANOL is used as a reagent in the discovery of quinoline-based single-ligand human H1 and H3 receptor antagonists. These antagonists are developed for the treatment of allergic rhinitis associated with nasal congestion. P-HYDOROXYPHENYL-4-BUTANOL plays a crucial role in the synthesis and development of these potential therapeutic agents, contributing to the advancement of treatments for respiratory conditions.

Upstream product

• 110-63-4 Butane-1,4-diol 
• 108-95-2 phenol 
• 52244-70-9 4-(4-methoxyphenyl)butan-1-ol 
• 1234665-22-5 4-(1-hydroxycyclobutyl)phenol 
• 1234665-32-7 1-oxaspiro[5.5]undeca-7,10-diene-2,9-dione 
• 1615654-57-3 4-(4-hydroxyphenyl)butyl acetate 
• 4521-28-2 4-(4-Methoxyphenyl)butyric acid 
• 3673-69-6 4-(3,5-di-tert-butyl-4-hydroxyphenyl)butanol 
• 7021-11-6 4-(4-hydroxyphenyl)butanoic acid 
• 13292-87-0 dimethyl sulfide borane 
• 102294-16-6 4-(4-benzyloxyphenyl)-3-buten-1-ol 

Downstream Products

• 748152-11-6 2,6-dibromo-4-(4-hydroxy-butyl)-phenol 
• 1160754-71-1 (S)-3-[4-(4-hydroxybutyl)phenoxy]propane-1,2-diol 
• 1160754-72-2 4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)phenyl]butan-1-ol 
• 92016-53-0 4-(4-Hydroxyphenyl)-butyramine 

Relevant academic research and scientific papers

GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE

The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Organocatalytic, Enantioselective Synthesis of Cyclohexadienone Containing Hindered Spirocyclic Ethers through an Oxidative Dearomatization/Oxa-Michael Addition Sequence

An unprecedented enantioselective oxa-Michael reaction of α-tertiary alcohols using cinchona-alkaloid-based chiral bifunctional squaramide catalysts is reported. An oxidative dearomatization of phenol followed by an enantioselective oxa-Michael addition s

Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists

Herein, we report studies leading to the discovery of the neoseptins and a comprehensive examination of the structure-activity relationships (SARs) of this new class of small-molecule mouse Toll-like receptor 4 (mTLR4) agonists. The compounds in this class, which emerged from screening an α-helix mimetic library, stimulate the immune response, act by a well-defined mechanism (mouse TLR4 agonist), are easy to produce and structurally manipulate, exhibit exquisite SARs, are nontoxic, and elicit improved and qualitatively different responses compared to lipopolysaccharide, even though they share the same receptor.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

NEOSEPTINS: SMALL MOLECULE ADJUVANTS

A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

DUAL MODULATION OF ENDOCANNABINOID TRANSPORT AND FATTY-ACID AMIDE HYDROLASE FOR TREATMENT OF EXCITOTOXICITY

The endocannabinoid transporter and FAAH are sites of modulation that allow pharmacological enhancement of protective endocannabinergic signals. Selective inhibitors of the transporter and inhibitors of FAAH caused additive augmentation of endogenous signaling events mediated by the cannabinoid CB1 receptor.Disruption of such signals has been shown to prevent neuronal maintenance processes and increase vulnerability to brain damage. Here, blocking endocannabinoid inactivation enhanced cannabinergic activity and ameliorated cellular disturbances associated with excitotoxicity. Modulating the endocannabinoid system in this way also prevented excitotoxic behavioral abnormalities including memory impairment. Collectively, these results indicate that increasing endocannabinoid responses by inhibiting the endocannabinoid transported and/or the inhibiting FAAH leads to molecular, cellular, and functional protection against excitotoxic insults like stroke and traumatic brain injury.

Organic synthesis using a hypervalent iodine reagent: Unexpected and novel domino reaction leading to spiro cyclohexadienone lactones

The reaction of 1-(p-hydroxyaryl)cyclobutanols and phenyl iodide(iii) diacetate in hexafluoroisopropanol and water produced spiro cyclohexadienone lactones via a domino reaction.

Thermolysis of 4-(ω-hydroxyalkyl)-2,6-di-tert-butylphenols

The process of thermolysis of tert-butylated hydroxyalkyl phenols includes de-tert-butylation, etherification, and fragmentation of the hydroxyalkyl group. On the basis of the proposed schemes of the mechanism of thermal de-tert-butylation the path of the search for catalysts for the synthesis of 4-hydroxyalkylphenols is defined and transformations of the by-products into biologically active substances were considered.